ALNY Stock Alnylam Pharmaceuticals (ALNY, $149.76) Moving Average Convergence Divergence (MACD) Histogram turned positive on June 4, 2024

GET DAILY SIGNALS

Get AI intraday signals

ALNY - Alnylam Pharmaceuticals

MACD signal

View

Odds of UP Trend

Price: $149.76

Daily change: -$0.69 (-0.46%)

Daily volume: 440.1K

Capitalization: $18.9B

Industry: Biotechnology

ALNY's Stochastic Oscillator is remaining in oversold zone for 2 days

Be on the lookout for a price bounce soon.

Technical Analysis (Indicators)

Bullish Trend Analysis

The RSI Oscillator points to a transition from a downward trend to an upward trend -- in cases where ALNY's RSI Indicator exited the oversold zone, of 20 resulted in an increase in price. Tickeron's analysis proposes that the odds of a continued upward trend are .

The Moving Average Convergence Divergence (MACD) for ALNY just turned positive on November 27, 2024. Looking at past instances where ALNY's MACD turned positive, the stock continued to rise in of 45 cases over the following month. The odds of a continued upward trend are .

ALNY may jump back above the lower band and head toward the middle band. Traders may consider buying the stock or exploring call options.

Bearish Trend Analysis

The Momentum Indicator moved below the 0 level on December 12, 2024. You may want to consider selling the stock, shorting the stock, or exploring put options on ALNY as a result. In of 89 cases where the Momentum Indicator fell below 0, the stock fell further within the subsequent month. The odds of a continued downward trend are .

ALNY moved below its 50-day moving average on November 12, 2024 date and that indicates a change from an upward trend to a downward trend.

The 10-day moving average for ALNY crossed bearishly below the 50-day moving average on November 11, 2024. This indicates that the trend has shifted lower and could be considered a sell signal. In of 20 past instances when the 10-day crossed below the 50-day, the stock continued to move higher over the following month. The odds of a continued downward trend are .

Following a 3-day decline, the stock is projected to fall further. Considering past instances where ALNY declined for three days, the price rose further in of 62 cases within the following month. The odds of a continued downward trend are .

The Aroon Indicator for ALNY entered a downward trend on November 27, 2024. This could indicate a strong downward move is ahead for the stock. Traders may want to consider selling the stock or buying put options.

Fundamental Analysis (Ratings)

The Tickeron Profit vs. Risk Rating rating for this company is (best 1 - 100 worst), indicating low risk on high returns. The average Profit vs. Risk Rating rating for the industry is 94, placing this stock better than average.

The Tickeron Price Growth Rating for this company is (best 1 - 100 worst), indicating steady price growth. ALNY’s price grows at a higher rate over the last 12 months as compared to S&P 500 index constituents.

The Tickeron Valuation Rating of (best 1 - 100 worst) indicates that the company is significantly overvalued in the industry. This rating compares market capitalization estimated by our proprietary formula with the current market capitalization. This rating is based on the following metrics, as compared to industry averages: ALNY's P/B Ratio (1000.000) is very high in comparison to the industry average of (14.678). P/E Ratio (0.000) is within average values for comparable stocks, (87.190). Projected Growth (PEG Ratio) (0.000) is also within normal values, averaging (1.782). ALNY has a moderately low Dividend Yield (0.000) as compared to the industry average of (0.012). P/S Ratio (14.925) is also within normal values, averaging (260.407).

The Tickeron PE Growth Rating for this company is (best 1 - 100 worst), pointing to worse than average earnings growth. The PE Growth rating is based on a comparative analysis of stock PE ratio increase over the last 12 months compared against S&P 500 index constituents.

The Tickeron SMR rating for this company is (best 1 - 100 worst), indicating weak sales and an unprofitable business model. SMR (Sales, Margin, Return on Equity) rating is based on comparative analysis of weighted Sales, Income Margin and Return on Equity values compared against S&P 500 index constituents. The weighted SMR value is a proprietary formula developed by Tickeron and represents an overall profitability measure for a stock.